PharmaGap Stock Price, News & Analysis (CVE:GAP)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About PharmaGap (CVE:GAP)

PharmaGap Inc. (PharmaGap) is a development-stage company. The Company is principally engaged in drug development and out-licensing of drug compounds. The Company is focused on the development of novel drugs for treatment of cancer and other human disease conditions. PharmaGap's lead drug compound, GAP-107B8, is in the pre-clinical testing stage and has shown in vitro and in vivo efficacy in selected cancer types. During the year ended December 31, 2011, the Company commenced specific programs to further elucidate information regarding the pharmacokinetics and toxicity profiles of GAP-107B8. A program to develop liposomal delivery formulations of GAP-107B8 in order to optimize the delivery and safety of the drug compound was completed during 2011. The Company is developing GAP-107B8 for first clinical trials in ovarian cancer, using the intra-peritoneal route of administration.

Receive GAP News and Ratings via Email

Sign-up to receive the latest news and ratings for GAP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolCVE:GAP
CUSIPN/A
WebN/A
Phone+1-613-2873118

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

PharmaGap (CVE:GAP) Frequently Asked Questions

What is PharmaGap's stock symbol?

PharmaGap trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GAP."

Who are some of PharmaGap's key competitors?

How do I buy PharmaGap stock?

Shares of PharmaGap and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How can I contact PharmaGap?

PharmaGap's mailing address is 1000 Innovation Drive, Suite 400, OTTAWA, ON K2K 2K7, Canada. The company can be reached via phone at +1-613-2873118.


MarketBeat Community Rating for PharmaGap (GAP)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  13 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  35
MarketBeat's community ratings are surveys of what our community members think about PharmaGap and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

PharmaGap (CVE:GAP) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for PharmaGap (CVE:GAP)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

PharmaGap (CVE:GAP) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for PharmaGap (CVE:GAP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for PharmaGap (CVE GAP)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

PharmaGap (CVE GAP) News Headlines

Source:
No headlines for this company have been tracked by MarketBeat.com

SEC Filings

PharmaGap (CVE:GAP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

PharmaGap (CVE GAP) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.